Comparative Pharmacology
Head-to-head clinical analysis: BACI RX versus BENSULFOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACI RX versus BENSULFOID.
BACI-RX vs BENSULFOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacitracin inhibits bacterial cell wall synthesis by interfering with the dephosphorylation of the lipid carrier that transports peptidoglycan precursors, thereby blocking cell wall formation.
Unknown; may inhibit Na+/K+-ATPase pump and increase renal sodium excretion
1-2 units/kg intramuscularly every 2-4 hours as needed for hemophilia A; intravenous infusion 40-50 units/kg for major surgery or life-threatening bleeding, then 20-25 units/kg every 8 hours.
Bensulfoid: not a recognized drug. No data available.
None Documented
None Documented
Terminal half-life: 2-3 hours in patients with normal renal function; prolonged to 20-40 hours in anuria. Clinical context: Dosing interval adjustment required for creatinine clearance <30 mL/min.
Terminal elimination half-life: 12-18 hours in adults with normal renal function; prolonged to 24-48 hours in moderate renal impairment (CrCl 30-50 mL/min).
Renal: 90-100% as unchanged drug via glomerular filtration; biliary/fecal: negligible.
Renal excretion of unchanged drug: 70-80%; biliary/fecal: 15-20%; metabolic inactivation accounts for the remainder.
Category C
Category C
Topical Antibiotic
Topical Antibiotic